Mucopolysaccharidosis I - 101 Studies Found Completed : Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) : Mucopolysaccharidosis II : 1999-10-18 : Genetic: lymphocyte gene therapy Recruiting : A Study of JR-141 in Patients With Mucopolysaccharidosis Type II : Mucopolysaccharidosis II : 2017-04-10 : Drug: JR-141 IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week Recruiting : The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients : Hunter Syndrome : 2014-01-19 Completed : A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723 : Mucopolysaccharidosis II : 2012-05-17 : Drug: Idursulfase recombinant Completed : Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase : Hunter Syndrome Mucopolysaccharidosis II< : 2008-02-28 : Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg once-weekly Recruiting : Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age : Hunter Syndrome : 2015-05-20 : Drug: Elaprase for intravenous (IV) infusion Patients enrolled in this study will receive once-weekly IV Completed : Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome : Hunter Syndrome : 2011-10-06 : Other: No treatment Completed : Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy : Hunter Syndrome Mucopolysaccharidosis II< : 2008-01-22 : Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg weekly Completed : An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients : Hunter Syndrome : 2009-04-16 : Biological: Idursulfase Patients received idursulfase as prescribed by their physician following locally Completed : A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® : Hunter Syndrome : 2009-06-12 : Other: Control 3 dose cohorts <<< Previous | Next >>>